The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: Electrophysiological correlates

Experimental Brain Research

Volumn 230, Issue 4, 2013, Pages 513-524

  Lagiere M ^a   Navailles, S ^a   Mignon, L ^b   Roumegous, A ^a   Chesselet, M F ^b   De Deurwaerdere P ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT agonists; 6 Hydroxydopamine; Basal ganglia; Entopeduncular nucleus; Purposeless oral movements

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; DOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; ENTOPEDUNCULAR NUCLEUS; HISTOPATHOLOGY; MALE; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; BASAL GANGLIA; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGICAL PHENOMENA; ENTOPEDUNCULAR NUCLEUS; ETHYLAMINES; GLOBUS PALLIDUS; INDOLES; MALE; NEURONS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SUBSTANTIA NIGRA;

EID: 84885659240     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-013-3478-4     Document Type: Article

References (53)

1. Adachi K, Hasegawa M, Fujita S, Sato M, Miwa Y, Ikeda H, Koshikawa N, Cools AR (2002) Dopaminergic and cholinergic stimulation of the ventrolateral striatum elicit rat jaw movements that are funnelled via distinct efferents. Eur J Pharmacol 442(1-2):81-92
2. Belforte JE, Pazo JH (2004) Turning behaviour induced by stimulation of the 5-HT receptors in the subthalamic nucleus. Eur J Neurosci 19(2):346-355
3. Beyeler A, Kadiri N, Navailles S, Boujema MB, Gonon F, Moine CL, Gross C, De Deurwaerdere P (2010) Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia. Neuroscience 169(1):158-170
4. Boraud T, Bezard E, Guehl D, Bioulac B, Gross C (1998) Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res 787(1):157-160
5. Brotchie P, Iansek R, Horne M (1991) A neural network model of neural activity in the monkey globus pallidus. Neurosci Lett 131(1):33-36
6. Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain J Neurol 130(Pt 7):1819-1833. doi: 10.1093/brain/awm082
7. Chase TN, Engber TM, Mouradian MM (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 44(7 Suppl 6):S15-S18
8. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13(7):277-280
9. De Deurwaerdere P, Chesselet MF (2000) Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J Neurosci 20(13):5170-5178
10. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24(13):3235-3241
11. De Deurwaerdere P, Le Moine C, Chesselet MF (2010) Selective blockade of serotonin 2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia. Neurosci Lett 469(2):251-255
12. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13(7):281-285
13. Di Giovanni G, Di Matteo V, La Grutta V, Esposito E (2001) m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Neuroscience 103(1):111-116
14. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G (2008) Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res 172:423-463
15. Dogali M, Fazzini E, Kolodny E, Eidelberg D, Sterio D, Devinsky O, Beric A (1995) Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 45(4):753-761
16. Eberle-Wang K, Lucki I, Chesselet MF (1996) A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72(1):117-128
17. Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997) Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384(2):233-247
18. Filip M, Bader M (2009) Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacological Rep: PR 61(5):761-777
19. Gong L, Kostrzewa RM (1992) Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol Biochem Behav 41(3):621-623
20. Gong L, Kostrzewa RM, Fuller RW, Perry KW (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 261(3):1000-1007
21. Gong L, Kostrzewa RM, Li C (1994) Neonatal 6-hydroxydopamine and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats. J Neurochem 63(4):1282-1290
22. Hassani OK, Feger J (1999) Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study. Neuroscience 92(2):533-543
23. Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244(6):320-324
24. Ikram H, Samad N, Haleem DJ (2007) Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak J Pharm Sci 20(3):188-195
25. Invernizzi RW, Pierucci M, Calcagno E, Di Giovanni G, Di Matteo V, Benigno A, Esposito E (2007) Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 144(4):1523-1535
26. Kaneoke Y, Vitek JL (1996) Burst and oscillation as disparate neuronal properties. J Neurosci Methods 68(2):211-223
27. Kita H, Chiken S, Tachibana Y, Nambu A (2007) Serotonin modulates pallidal neuronal activity in the awake monkey. J Neurosci 27(1):75-83. doi: 10.1523/JNEUROSCI.4058-06.2007
28. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370(2):114-123. doi: 10.1007/s00210-004-0951-4
29. Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70(3):889-898
30. Kostrzewa RM, Huang NY, Kostrzewa JP, Nowak P, Brus R (2007) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 11(1):41-50
31. Labarre D, Meissner W, Boraud T (2008) Measure of the regularity of events in stochastic point processes, application to neuron activity analysis. 33rd IEEE International Conference on Acoustics, Speech and Signal Processing, Las Vegas, NV. pp 489-492
32. Lagiere M, Navailles S, Bosc M, Guthrie M, De Deurwaerdère P (2013) Serotonin2C receptors and the motor control of oral activity. Curr Neuropharmacol (in press)
33. Lang AE, Duff J, Saint-Cyr JA, Trepanier L, Gross RE, Lombardi W, Montgomery E, Hutchinson W, Lozano AM (1999) Posteroventral medial pallidotomy in Parkinson's disease. J Neurol 246(Suppl 2):II28-II41
34. Liminga U, Johnson AE, Andren PE, Gunne LM (1993) Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat. Pharmacol Biochem Behav 46(2):427-433
35. Mehta A, Eberle-Wang K, Chesselet MF (2001) Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons. Pharmacol Biochem Behav 68(2):347-353
36. Mongeau R, Martin CB, Chevarin C, Maldonado R, Hamon M, Robledo P, Lanfumey L (2010) 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem 115(2):438-449
37. Navailles S, De Deurwaerdere P (2012) Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. Mol Neurobiol 45(1):173-185. doi: 10.1007/s12035-011-8230-0
38. Navailles S, Benazzouz A, Bioulac B, Gross C, De Deurwaerdere P (2010a) High-frequency stimulation of the subthalamic nucleus and L-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci 30(6):2356-2364
39. Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010b) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 38(1):136-143. doi: 10.1016/j.nbd.2010.01.012
40. Navailles S, Lagiere M, Roumegous A, Polito M, Boujema MB, Cador M, Dunlop J, Chesselet MF, Millan MJ, De Deurwaerdere P (2013) Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. Int J Neuropsychopharmacol 16(3):593-606. doi: 10.1017/S1461145712000417
41. Numan S, Lundgren KH, Wright DE, Herman JP, Seroogy KB (1995) Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 29(2):391-396
42. Pact V, Giduz T (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 53(5):1154
43. Parry TJ, Eberle-Wang K, Lucki I, Chesselet MF (1994) Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats. Exp Neurol 128(2):181-190. doi: 10.1006/exnr.1994.1126
44. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92(2):601-611
45. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, San Diego
46. Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology 119(4):466-473
47. Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23(1-2):163-178
48. Sgambato V, Abo V, Rogard M, Besson MJ, Deniau JM (1997) Effect of electrical stimulation of the cerebral cortex on the expression of the Fos protein in the basal ganglia. Neuroscience 81(1):93-112
49. Stewart BR, Jenner P, Marsden CD (1989) Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. Eur J Pharmacol 162(1):101-107
50. Sutton JP, Couldwell W, Lew MF, Mallory L, Grafton S, DeGiorgio C, Welsh M, Apuzzo ML, Ahmadi J, Waters CH (1995) Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease. Neurosurgery 36(6):1112-1116 (discussion 1116-1117)
51. Wolf WA, Bieganski GJ, Guillen V, Mignon L (2005) Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced early onset vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology 182(1):84-94
52. Zhang X, Andren PE, Svenningsson P (2007) Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol Behav 92(1-2):29-33. doi: 10.1016/j.physbeh.2007.05.033
53. Zhang QJ, Liu X, Liu J, Wang S, Ali U, Wu ZH, Wang T (2009) Subthalamic neurons show increased firing to 5-HT2C receptor activation in 6-hydroxydopamine-lesioned rats. Brain Res 1256:180-189